Showing 6151-6160 of 9788 results for "".
- SENTÉ Partners with Scientis to Introduce Cysperahttps://practicaldermatology.com/news/sente-partners-with-scientis-to-introduce-cyspera/2460146/SENTÉ is partnering with Scientis, a Swiss dermatology company dedicated to developing novel dermo-cosmetic solutions to address skin pigmentation concerns, to introduce Cyspera®. Cyspera, a physician exclusive skincare product, is a novel intensive
- Innovations In Skin Of Color Dermatology Award Presented to Dr. Andrew F. Alexishttps://practicaldermatology.com/news/innovations-in-skin-of-color-dermatology-award-presented-to-dr-andrew-f-alexis/2460140/The Journal of Drugs in Dermatology (JDD) presented dermatologist Andrew F. Alexis, MD, MPH, with the Innovations in Skin of Color Dermatology Award at Skin of Color Update, formerly Skin of Color Seminar Series, held September 7 and 8 in New York. The award recognizes individuals who ha
- ASDS 2018 Survey: Skin Cancer Treatments and Cosmetic Procedures are on the Risehttps://practicaldermatology.com/news/asds-2018-survey-skin-cancer-treatments-and-cosmetic-procedures-are-on-the-rise/2460133/American Society for Dermatologic Surgery (ASDS) member dermatologists performed more than 12.5 million medical and cosmetic procedures in 2018 – 7.5 percent more than 2017 and a 60 percent increase since 2012, according to the 2018 ASDS
- Cassiopea Submits NDA for New Acne Treatmenthttps://practicaldermatology.com/news/cassiopea-submits-nda-for-new-acne-treatment/2460131/Cassiopea SpA submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for clascoterone cream 1% for the treatment of acne. Clascoterone cream 1% is under investigation as a first-in-class topical androgen receptor inhibitor for th
- Blocking LSD1 May Thwart Common Skin Cancer Growthhttps://practicaldermatology.com/news/blocking-lsd1-may-thwart-common-skin-cancer-growth/2460130/The outer layer of the skin completely replaces itself every two to four weeks, but when this process is blocked, cancer can grow. A new study from researchers in the Perelman School of Medicine at the University of Pennsylvania has now identifie
- Dr. Jennifer Soung Named New Psoriasis Editorhttps://practicaldermatology.com/news/dr-jennifer-soung-named-new-psoriasis-editor/2460129/Practical Dermatology magazine is pleased to announce that Jennifer Soung, MD is the new psoriasis editor. Dr. Soung, a dermatologist at Southern California Dermatology in Santa Ana, CA, will replace Jerry Bagel, MD. Her first feature article is slated to in the November 2
- Study Shows StrataGraft-treated Deep Partial-thickness Burns Did Not Require Surgical Harvest of Healthy Skinhttps://practicaldermatology.com/news/study-shows-stratagraft-treated-deep-partial-thickness-burns-did-not-require-surgical-harvest-of-healthy-skin/2460127/Mallinckrodt plc shared results of its Phase 1b clinical trial of StrataGraft, an investigational regenerative tissue, in Burns, the journal of the International Society for Burn Injuries (ISBI). Study data showed that treatment with a single application of StrataGraft tissue resulted in
- PE in Dermatology: NavaDerm Partners with Laser & Skin Surgery Center of NYhttps://practicaldermatology.com/news/pe-in-dermatology-navaderm-partners-with-laser-skin-surgery-center-of-ny/2460119/NavaDerm is partnering with Laser & Skin Surgery Center of New York, Midtown Dermatology and their affiliated entities. Navaderm is a dermatology services organization in the Northeast and a BelHealth Investm
- Complete Wound Healing Seen on Index Lesion of the First Subject in an Ongoing Phase 2 Trial of RGN-137 Dermal Gel for EBhttps://practicaldermatology.com/news/complete-wound-healing-seen-on-index-lesion-of-the-first-subject-in-an-ongoing-phase-2-trial-of-rgn-137-dermal-gel-for-eb/2460118/Lenus Therapeutics, LLC, a US-based joint venture between GtreeBNT and Yuyang DNU in Korea, has confirmed complete wound healing of the index lesion of the first subject enrolled in its ongoing single-masked Phase 2 clinical trial with RGN-137 dermal gel for Epidermolysis Bullosa (EB).
- Foamix Submits NDA for FMX103 for the Treatment of Moderate-to-Severe Papulopustular Rosaceahttps://practicaldermatology.com/news/foamix-submits-nda-for-fmx103-for-the-treatment-of-moderate-to-severe-papulopustular-rosacea/2460117/Foamix Pharmaceuticals Ltd. has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for FMX103 for the treatment of moderate-to-severe papulopustular rosacea in patients 18 years of age and older